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The four-and-half LIM domain protein 1 (FHL1) is highly expressed in skeletal and cardiac
muscle. Mutations of the FHL1 gene have been associated with diverse chronic myopathies
including reducing body myopathy, rigid spine syndrome (RSS), and Emery–Dreifuss mus-
cular dystrophy. We investigated a family with a mutation (p.C150R) in the second LIM
domain of FHL1. In this family, a brother and a sister were affected by RSS, and their mother
had mild lower limbs weakness.The 34-year-old female had an early and progressive rigid-
ity of the cervical spine and severe respiratory insufficiency. Muscle mass evaluated by
DXA was markedly reduced, while fat mass was increased to 40%. CT scan showed an
almost complete substitution of muscle by fibro-adipose tissue. Muscle biopsy showed
accumulation of FHL1 throughout the cytoplasm and around myonuclei into multiprotein
aggregates with aggresome/autophagy features as indicated by ubiquitin, p62, and LC3
labeling. DNA deposits, not associated with nuclear lamina components and histones, were
also detected in the aggregates, suggesting nuclear degradation. Ultrastructural analysis
showed the presence of dysmorphic nuclei, accumulation of tubulofilamentous and gran-
ular material, and perinuclear accumulation of autophagic vacuoles. These data point to
involvement of the aggresome–autophagy pathway in the pathophysiological mechanism
underlying the muscle pathology of FHL1 C150R mutation.
Keywords: myopathy, sarcopenia, FHL1, autophagy, protein aggregates
INTRODUCTION
Four-and-half LIM domain protein 1 (FHL1) is a cysteine-rich
double zinc-finger protein encoded by the FHL1 gene, localized on
chromosome X (Dawid et al., 1995; Kadrmas and Beckerle, 2004).
To date, three distinct FHL1 splicing isoforms have been identi-
fied (Brown et al., 1999; Morgan and Madgwick, 1999; Ng et al.,
2001; Purcell et al., 2004; Johannessen et al., 2006; McGrath et al.,
2006). FHL1A, also known as skeletal muscle LIM protein 1, is the
full-length protein. FHL1B, or SLIMMER, is composed of the first
three LIM domains and contains nuclear localization and export
sequences and a RBP-J binding region. FHL1C, or KyoT2, is the
shortest isoform, which contains only the first two LIM domains
and a RBP-J binding region and interacts with PIAS1 (Taniguchi
et al., 1998; Wang et al., 2007).
Four-and-half LIM domain protein 1 is highly expressed in
skeletal and cardiac muscles (Lee et al., 1998; Brown et al., 1999;
Greene et al., 1999; Morgan and Madgwick, 1999), where it
localizes in the myofibrillar sarcomeres and in the sarcolemma
(Bertrand et al., 2014). This protein has been demonstrated to
be involved in several processes, including cellular architecture
(McGrath et al., 2003, 2006), myoblast differentiation (Lee et al.,
2012), mechanotransduction (Sheikh et al., 2008), and myofiber
size (Cowling et al., 2008). FHL1 binds signaling and cytoskeletal
proteins as well as transcription factors, acting as a transcriptional
regulator of nuclear factor of activated T cells (NFATc1) to enhance
the expression of genes that increase myofiber size (Cowling et al.,
2008).
Mutations in the FHL1 gene are responsible for a number
of muscular disorders, which exhibit a broad spectrum of clin-
ical features and disease severity ranging from severe childhood
onset to milder adult-onset disorders. The diseases described
so far include X-linked myopathy with postural muscle atrophy
(XMPMA) (Windpassinger et al., 2008), reducing body myopathy
(RBM) (Schessl et al., 2009; Shalaby et al., 2009; Selcen et al., 2011;
Schreckenbach et al., 2013), X-linked dominant scapuloperoneal
myopathy (Quinzii et al., 2008; Chen et al., 2010), rigid spine syn-
drome (RSS) (Shalaby et al., 2008), hypertrophic cardiomyopathy
(Friedrich et al., 2012), and Emery–Dreifuss muscular dystrophy
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 215 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sabatelli et al. Aggresome–autophagy involvement in FHL1 pathogenesis
(Gueneau et al., 2009; Knoblauch et al., 2010). RBM is charac-
terized by the presence of intracellular protein aggregates called
“reducing bodies (RBs)”mainly containing mutated FHL1 protein,
cytoskeletal and intermediate filament proteins, and components
of the unfolded protein response pathway (Liewluck et al., 2007).
Although scapuloperoneal myopathy, XMPMA, RSS, hypertrophic
cardiomyopathy, and Emery–Dreifuss muscular dystrophy share
some overlapping clinical features and muscle pathology with
RBM, the involvement of protein aggregation in these disorders
remains unclear (Wilding et al., 2014).
Reducing bodies morphologically resemble aggresomes, struc-
tures proposed to facilitate the sequestration, and degradation
of toxic misfolded proteins. Non-functional, damaged, and/or
misfolded proteins are removed from the cell by the ubiquitin
proteasome system. However, when the capacity of the protea-
some is impaired or overwhelmed, polyubiquitinated misfolded
proteins cannot be properly cleared and accumulate into the aggre-
some (Goldberg, 2003; Kawaguchi et al., 2003). Accumulating
evidence suggests that aggresomes are substrates for autophagy.
Autophagy is a degradation pathway that mediates bulk clear-
ance of cytosolic proteins and organelles by the lysosome in a
highly regulated process involving the coordinated actions of a
large number of autophagy-related (Atg) genes. In response to
particular stimuli, such as proteasomal dysfunction, an isolation
membrane forms and expands to sequester portions of cytoplasm
into double membrane structures called autophagosomes. The
autophagosomes eventually fuse with lysosomes and their con-
tents are degraded by lysosomal hydrolases. One hypothesis is that
aggresomes may concentrate aggregated proteins for more effi-
cient autophagic degradation (Bjorkoy et al., 2005, 2006; Iwata
et al., 2005). Recent evidence indicates that aggresome formation
is mediated by dynein/dynactin-mediated transport of misfolded
proteins to the centrosome and involves several regulators, includ-
ing the E3 ubiquitin-protein ligase parkin (Olzmann et al., 2008).
Aggresome clearance is mediated by ubiquitin-binding proteins
such as p62/SQSTM1 (Kirkin et al., 2009), an adaptor protein
that decides the fate of protein degradation either through the
ubiquitin proteasome system or the autophagy–lysosome pathway
(Komatsu et al., 2007; Kirkin et al., 2009; Komatsu and Ichimura,
2010). Here, we report evidence of aggresome and autophagy
involvement in the muscle of a sarcopenic patient with RSS and
p.C150R mutation in the FHL1 gene.
MATERIALS AND METHODS
GENOTYPING
The six coding exons and introns boundaries of FHL1
(NM_001159702) were screened for mutations by PCR on DNA
from peripheral lymphocytes using primer pairs with a universal
sequence (Table on demand). Exon 5 was sequenced with primers:
5PUF: 5′−ACCGTTAGTATGCGAGTTGGATTCAGGCAC
TGGATCCTA− 3′
5PUR: 5′−TCGGATAGTCAGTCGTTTGCTGTCGTGAGG
ATGGAATG− 3′.
Analysis of sequences was done with SeqScape software
(Applied Biosystem).
MUSCLE BIOPSY
Peroneal muscle biopsy of the 34-year-old female was performed
after written informed consent, and approval was obtained from
the Ethics Committee of the Rizzoli Orthopedic Institute. The
muscle sample was frozen in melting isopentane and stored in
liquid nitrogen.
HISTOCHEMISTRY AND IMMUNOHISTOCHEMICAL ANALYSIS
Standard histochemical study was performed, and congophilic
deposits were identified by Congo red staining (Bioptica) follow-
ing the manufacturer’s instructions. Cytochrome oxidase activity
was assessed by conventional method. Acridine-orange staining
was performed as previously reported (Darzynkiewicz, 1994). For
double staining with menadione–nitro blue tetrazolium and anti-
FHL1 antibodies,10µm-thick frozen sections were incubated with
menadione-NBT solution in Gomori-Tris-HCl buffer at pH 7.4,
without the addition of α-glycerophosphate substrate (Brooke and
Neville, 1972), followed by incubation with anti-FHL1 antibody
(Aviva System) and TRITC conjugated anti-rabbit secondary anti-
body (DAKO). Seven micrometer-thick non-fixed frozen sections
were incubated with antibodies against laminin α2 chain, colla-
gen VI, parkin (Millipore), desmin, developmental myosin heavy
chain (d-MHC), fast myosin heavy chain, dystrophin (DYS1,
DYS2, and DYS3 antibodies), emerin, lamin A/C (Novocastra),
LC3 (Novus Biologicals), p62 (Progen Biotechnik), pericentrin,
α-B-crystallin (Abcam), ubiquitin (Santa Cruz Biotechnologies),
and histones (Chemicon), and revealed with FITC or TRITC
conjugated anti-rabbit, anti-mouse, or anti-guinea pig secondary
antibodies. Samples were stained with DAPI, mounted with anti-
fading reagent (Molecular Probes), and observed with a Nikon
epifluorescent/light microscope.
CONFOCAL IMAGING
The confocal imaging was performed with a A1-R confocal laser
scanning microscope (Nikon), equipped with a Nikon 60×, 1.4
NA objective, and with a 488 and 561 nm laser lines to excite FITC
(green) and TRITC (red) fluorescence signals. The 3D images were
processed by stacking up 20–25 consecutive confocal images with
surface shaded reconstruction. No deconvolution was applied to
the images.
TRANSMISSION ELECTRON MICROSCOPY
Muscle biopsy was fixed with 2.5% glutaraldehyde in 0.1 M cacody-
late buffer pH 7.4 for 3 h at 4°C, post-fixed with 1% osmium
tetroxide in cacodylate buffer for 2 h, dehydrated in an ethanol
series, infiltrated with propylene oxide and embedded in Epon 812
resin. Ultrathin sections were stained with uranyl acetate and lead
citrate (Reynolds) and examined under a Philips EM400 operating
at 100 kV.
WESTERN BLOTTING
Twenty micrometer-thick frozen sections were cut from the mus-
cle biopsy of a healthy individual and of the proband patient.
Sections were taken from two different portions of the patient
muscle biopsy (referred as Pa and Pb). Muscle sections were
lysed in 150µl lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl,
10 mM MgCl2, 1 mM EDTA, 10% glycerol, 0.5 mM DTT, 2%
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sodium dodecyl sulfate, 1% Triton X-100) supplemented with
phosphatase inhibitors (Sigma-Aldrich) and protease inhibitors
(Roche), heated at 70°C for 10 min and centrifuged at 16,100 g for
10 min at 4°C. The protein content of each lysate was determined
by the BCA Protein Assay kit (Pierce) and 30µg of total proteins
were separated by SDS-PAGE (Invitrogen) and immunoblotted as
previously described (Chen et al., 2014). Membranes were probed
with primary antibodies against FHL1 (ab23937 Abcam), LC3
(Thermo Scientific), p62 (Progen Biotechnik), ubiquitin (Cell Sig-
naling Technologies), beclin 1 (Cell Signaling), BNIP3 (Sigma),
vinculin (Sigma), or GAPDH (Millipore). Proteins were revealed
with anti-rabbit, -mouse (Bethyl), -goat (Santa Cruz Biotechnolo-
gies), or -guinea pig (Sigma) HRP-conjugated secondary antibod-
ies using the ECL reagent (Pierce-Thermo Scientific). Densitomet-
ric quantification of protein bands was performed by the ImageJ
software (US National Institute of Health). Western blotting and
quantifications are representative of at least three independent
experiments.
RESULTS
The proband is a 34-year-old woman who noticed the inability
to extend the right thumb at age 20. Soon after, she manifested
neck weakness and limitation of flexion. Progression of weakness
was rapid and she started to have difficulty in climbing stairs and
getting up from the floor. At age 24, she started falling several
times while walking. At age 26, the patient lost ambulation and
was wheelchair bound. Examination at age 34 showed an atrophic
phenotype with marked diffuse muscle wasting and weakness and
prominent contractures. She had normal facial muscle strength,
a minimal residual motor function in the elbow extensors and in
the right biceps, but was profoundly weak in all the other muscles.
She revealed marked contractures involving proximal and distal
joints. The most striking contractures were in the neck muscles
causing a fixed hyperextended neck that was also impossible to
move in any direction. She showed a progressive decline in the
respiratory function with a forced vital capacity 59% of predicted
at age 25, 45% at age 27, and 13% at age 34. She refused to undergo
mechanical ventilation. Cardiac investigation, including echocar-
diography and Holter, revealed no cardiac involvement. Muscle
CT showed that all muscles were atrophic and substituted by fat
and connective tissue, including the axial muscles, with a minimal
sparing of the rectus femoris and vastus lateralis on the left, and
of the peroneus on the right (Figure 1A). She was underweight
(BMI= 17.1). However, according to her body composition, as
revealed by DXA, she was sarcopenic/obese (appendicular lean
body mass index of 3.27 kg/m2 and total body fat of 44.4%)
(Baumgartner et al., 2004). Her brother had a similar atrophic
phenotype with marked rigidity of the spine and diffuse contrac-
tures but with more rapid progression, as he lost ambulation at
age 18 and underwent tracheostomy at age 28. Their mother at
age 58 had a mild lower limbs weakness and no contractures.
Sequencing of the FHL1 gene in the index case identified a
single missense mutation c.448T>C in exon 5 resulting in the
replacement at codon 150 of a cysteine residue with an arginine
residue (p.Cys150Arg). Nucleotide c.448 and residue p.150 of the
FHL1 gene are highly conserved among species and evolution,
and all prediction softwares conclude for a pathogenic mutation.
Analysis of the family showed that her brother and mother also
have the same FHL1 mutation.
Muscle biopsy showed fiber size variability, numerous internal
nuclei, and increased endomysial and perimysial tissue. Several
muscle fibers showed menadione-NBT positive aggregates, con-
sistent with the presence of RBs (Figure 1B). RBs were devoid of
oxidative enzyme activity and displayed an intense congophilia,
indicative of the presence of amyloid deposits. Immunohisto-
chemistry with FHL1 antibody revealed the presence of protein
aggregates in about 20% of muscle fibers. Consistent with previ-
ous reports (Selcen et al., 2011; Feldkirchner et al., 2013; Bertrand
et al., 2014), FHL1 deposits were detected throughout the cyto-
plasm and around myonuclei. Double staining with menadione-
NBT revealed that FHL1 deposits strongly correlated with RBs,
although with a more diffuse pattern. Desmin and α-B-crystallin
(not shown) were strongly up-regulated in affected muscle fibers
but they did not co-localize with FHL1 deposits (Figure 1 and data
not shown). Sarcolemmal components, such as dystrophin and
laminin α2, were not detected in RBs; collagen VI was increased
in the endomysium and perimysium, possibly as a consequence of
active fibrosis (data not shown).
Reducing bodies displayed aggresome features as indicated
by association with ubiquitin and with the luminal endoplas-
mic reticulum chaperone Grp78, in agreement with a previous
work (Wilding et al., 2014). Consistent with aggresome formation,
parkin, an E3 ubiquitin ligase involved in retrograde transport of
misfolded proteins to centrosome (Garcia-Mata et al., 1999), and
pericentrin, a marker of centrosome, were increased in affected
myofibers (Figure 2A). Western blot analysis showed a patient-
specific increase of ubiquitin (Figure 2B), confirming the massive
presence of aberrant ubiquitinated proteins. Western blotting for
FHL1 in the soluble fraction of patient muscle biopsy showed
no significant change of FHL1 protein levels with respect to the
control (Figure 2C).
Confocal imaging revealed a clear co-localization of FHL1
with p62 labeling (Figure 2D). FHL1/p62-positive aggregates also
stained with DAPI, indicating the presence of nuclear mater-
ial. Interestingly, DAPI-positive structures were not surrounded
by nuclear lamina, as indicated by the absence of lamin A/C
(Figure 3A) and emerin (not shown). In addition, DAPI-positive
structures did not associate with histones (Figure 3B) and dis-
played an intense red fluorescence when stained with acridine
orange (Figure 3C), a metachromatic dye that differentially stains
double-stranded DNA and single-stranded DNA or RNA. Notably,
DNase treatment strongly reduced the acridine-orange staining
(Figure 3D). Altogether, these data suggest that FHL1/p62 aggre-
gates also include single-stranded DNA, possibly due to nuclear
degradation.
Recent studies have suggested that aggresomes are substrates
for autophagy (Yao, 2010). LC3 immunolabeling on the patient
muscle biopsy revealed the presence of autophagosomes in prox-
imity of p62 aggregates (Figure 4A), suggesting the involvement of
the autophagic pathway in aggresome clearance. Moreover, analy-
sis of the protein levels of several autophagic markers showed a
strong accumulation of p62, confirming the presence of an ele-
vated number of aggresomes (Figures 4B,C). Notably, Beclin 1
and BNIP3, two well-known positive regulators of autophagy, were
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FIGURE 1 | (A) Patient with FHL1 mutation: index case. Muscle CT imaging of
the neck (a), left thigh (b), pelvis (c), lower legs (d), and abdominal (e) muscles.
In the neck, there is a relative preservation of the left sternocleidomastoideus
(1) and almost complete involvement of all the other muscles (a). In the left
thigh, only the rectus femoris (2) and vastus lateralis (3) are relatively spared
(b). In the pelvis (c) and in the abdomen (e), there is a marked degeneration of
all muscles. In the lower legs, only the peroneus (4) of the right leg is
relatively spared (d). (B) Histochemistry and immunohistochemical analysis of
patient muscle biopsy. Cross-sections show the presence of RBs in several
muscle fibers, as revealed by menadione-NBT staining (a). Granular deposits
are detectable at the nuclear rim of some myonuclei (a, inset). RBs appear
devoid of oxidative activity (cytochrome oxidase, COX in b) and display affinity
to Congo red staining (c). Immunofluorescence analysis of FHL1 shows
protein accumulation throughout the cytoplasm of several muscle fibers (d)
and around myonuclei (d, inset). FHL1 immunolabeling (e), followed by
menadione-NBT staining (f), demonstrates that FHL1 accumulates in RBs (f).
Double labeling for FHL1 and desmin (g–i) shows a marked increase of
desmin in FHL1-accumulating myofibers. Scale bar, 20µm.
strongly increased in the patient biopsy, indicating that autophagy
induction is taking place, likely in response to the need of clearing
the accumulating aggregates. This was further confirmed by the
slight increase of LC3 lipidation observed in the patient biopsy
(Figures 4B,C). All together, these data indicate that autophagy is
strongly induced in the muscle biopsy from the patient.
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FIGURE 2 | (A) Double labeling of FHL1 with pericentrin, parkin, ubiquitin,
and Grp78 in cross-sections of patient muscle biopsy. Scale bar, 20µm.
(B)Western blot analysis for ubiquitin in total protein extracts from muscle
biopsies derived from a healthy donor (C) and from the patient (two
different fragments of the index case biopsy, Pa and Pb). Increased
reactivity for ubiquitin is clearly detectable in patient extracts. Ponceau S
staining is shown as loading control. (C)Western blot analysis for FHL1 and
vinculin in total protein extracts from muscle biopsies derived from a
healthy donor (C) and from the index case (Pa and Pb). Quantification of the
FHL1 protein level showing the relative western blot intensity with respect
to control. Densitometric quantification was performed by three
independent western blot experiments (P >0.05, Pa and Pb vs C).
(D) Confocal immunofluorescence imaging of the patient muscle biopsy
labeled with FHL1 antibody (red), p62 antibody (green), and DAPI (blue). The
maximum intensity projections of the single channels (white) are shown on
the left, the merged image of confocal projections are shown in the middle,
and the 3D surface shaded reconstruction of an enlargement of the area
defined by the white box is shown on the right. Scale bar, 10µm.
Ultrastructural analysis showed cytoplasmic bodies and
tubulofilamentous material associated with nuclear alterations
and autophagic vacuoles (Figure 5). Tubulofilamentous aggregates
ranged from 14 to 1.2 nm. Dysmorphic nuclei showed condensed
heterochromatin, ribonucleoprotein aggregates, enlarged nucleoli,
and condensed granular material at the outer face of the nuclear
cisterna. In addition, a reduced number of nuclear pores were
also detected in nuclei with hypercondensed heterochromatin.
Autophagic vacuoles, and in particular autophagolysosomes as
indicated by the presence of a single membrane, were frequently
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FIGURE 3 | Continued
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FIGURE 3 | Continued
(A) Confocal immunofluorescence imaging of the patient muscle biopsy
labeled with FHL1 antibody (red), lamin A/C antibody (green), and DAPI (blue).
The maximum intensity projections of red and green channels (white) are
shown on the left, the merged image of confocal projections are shown in the
middle, and the 3D surface shaded reconstruction of an enlargement of the
area defined by the white box is shown on the right. (B) Confocal
immunofluorescence imaging of the patient muscle biopsy labeled with an
anti-histones antibody (green) and DAPI (blue), together with 3D surface
shaded reconstruction (merge). (C) Acridine-orange staining. The maximum
intensity projections of the single channels (white) are shown on the left, the
merged image of confocal projections are shown in the middle, and the 3D
surface shaded reconstruction of an enlargement of the area defined by the
white box is shown on the right. (D) Acridine-orange staining after DNase
digestion on frozen sections of the patient’s muscle biopsy showing that the
treatment completely removed nuclear and RBs associated DNA. The
maximum intensity projections of the red and green channels (white) are
shown on the left, the merged image of confocal projections are shown in the
middle, and the 3D surface shaded reconstruction of the area defined by box
is shown on the right. Scale bar, 10µm.
FIGURE 4 | (A) Confocal immunofluorescence imaging of the patient muscle
biopsy labeled with LC3 antibody (red), p62 antibody (green), and DAPI (blue).
The maximum intensity projections of the single channels (white) are shown
on the left, the merged image of confocal projections are shown in the
middle, and the 3D surface shaded reconstruction of an enlargement of the
areas defined by the white boxes are shown on the right. Scale bar, 10µm.
(B)Western blot analysis for the autophagic markers LC3, Beclin 1, BNIP3,
and p62 in muscle biopsies derived from a healthy donor (C) and from the
index case (Pa and Pb). GAPDH was used as a loading control. (C) Quantifica-
tion of the protein levels showing the relative western blot intensity with
respect to control. Densitometric quantification was performed by three
independent western blot experiments (***P < 0.001; **P <0.01; *P <0.05).
found in proximity of altered nuclei. Other inclusions consisted
of myelinic bodies and aggregates of sarcoplasmic reticulum.
DISCUSSION
In this work, we provided data showing that aggresome
and autophagy are involved in the pathophysiological defects
underlying the muscle pathology of a sarcopenic patient with RSS
and carrying a FHL1 p.C150R mutation.
In our family, the female index case and her brother had a
typical RSS (Moghadaszadeh et al., 2001). The p.C150R muta-
tion has already been reported in patients with RSS (Schessl et al.,
2010; Selcen et al., 2011). Interestingly, another female patient
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FIGURE 5 |Transmission electron microscopy of patient muscle
biopsy. (A–D) Images showing cytoplasmic body (asterisk) and
tubulofilamentous aggregates (arrowhead) close to degenerated nuclei
(N). Higher magnification of the areas defined by boxes in (A) is shown
in (B–D). (E,F) Images showing altered nuclei with granular material
accumulated at the nuclear rim. (G) Images showing dilated
sarcoplasmic reticulum filled with amorphous material in a myofiber.
(H–J) Images showing autophagic vacuoles and myelin figures close to
nuclei and throughout some sarcomeres of muscle fibers. Scale bar,
500 nm.
(Selcen et al., 2011) presented extensor pollicis weakness, which
was the first symptom noticed by our index case. Our patient had
an atrophic phenotype. Underweight by body mass index, she was
recognized to be sarcopenic-obese as determined by DXA given
the marked reduction of lean body mass with relative increase
of fat mass (Baumgartner et al., 2004). The sarcopenic condi-
tion was also reflected in the muscle CT that showed diffuse end
stage degeneration. The brother of the index case had a severe
progressive course; he lost ambulation at age 18, and underwent
tracheostomy at age 28. In previously reported families, male
patients were the most affected, while female carriers showed
varying manifestations usually mild and some were asymptomatic
(Schessl et al., 2010; Selcen et al., 2011). In our family, the two
female patients had a very different course: severe and progres-
sive in the index case and mild in her mother who was ambulant
and without spine rigidity at age 58. Because of X chromosome
inactivation, heterozygous women are mosaic for X-linked gene
expression. This may explain the much milder phenotype in the
mother compared with that of her daughter (Schessl et al., 2010;
Selcen et al., 2011). The less affected mother was also much less
atrophic, pointing to a possible differential activation of muscle
atrophy pathways. However, no muscle biopsy of the mother was
available, and X-inactivation studies were not performed in this
family.
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Muscle findings included menadione-NBT-positive aggregates,
consistent with RBs, which also contained FHL1. The same FHL1
mutation was previously reported in a family with RBM phenotype
(Schessl et al., 2010) and in two patients with RBs and myofib-
rillar myopathy (Selcen et al., 2011). Also in those patients, the
mutated FHL1 protein accumulated in RBs, pointing to a causative
effect of this mutation in RB formation. The mutated cysteine
residue localizes in the second LIM domain of the protein and it is
expected to affect all FHL1 isoforms, i.e., full-length FHL1A and
the shorter FHL1B and FHL1C polypeptides. Cys150 is a crucial
coordinating residue in the second LIM domain (Michelsen et al.,
1994) and mutations occurring at this site are predicted to induce
protein misfolding. It has been proposed that the accumulation
of misfolded FHL1 polypeptides results in the characteristic RB
aggregates observed in muscle of RBM patients as well as in C2C12
myoblasts transfected with the mutant FHL1 protein (Schessl et al.,
2008).
Aggresomes are structures proposed to facilitate the sequestra-
tion and degradation of toxic misfolded proteins. In agreement
with previous reports (Bertrand et al., 2014), the RBs of the
proband displayed characteristics of aggresomes, as indicated by
the increase of proteins involved in aggresome formation and
by the accumulation of ubiquitin, Grp78, p62, and cytoskeletal
components, such as desmin and α-B-crystallin. Moreover, the
FHL1-containing aggresomes were mainly accumulated around
nuclei. It is well known that aggresome formation is mediated by
the dynein/dynactin-mediated transport of misfolded proteins to
the centrosome, as confirmed by the presence of aggresomes in
the perinuclear region and matching with centrosome markers
(Olzmann et al., 2008). In muscle cells, the centrosome undergoes
redistribution at the nuclear rim during differentiation (Bugnard
et al., 2005). This pattern persists in adult muscle (Srsen et al.,
2009), as indicated by the localization of centrosome markers
on the outer membrane of the nuclear cisterna. This peculiar
positioning of the centrosome at the nuclear rim of muscle cells
accounts for the recruitment of granular material with aggresome-
like features we observed in nuclei of the FHL1 mutated muscle
fibers. In addition, we found that nuclei with perinuclear gran-
ular material appeared dysmorphic, with dramatic changes of
the nuclear envelope and hypercondensed heterochromatin. These
data, in addition to the finding of single-stranded DNA in aggre-
somes, suggest that the aggresome accumulation at the nuclear rim
may induce nuclear degradation. This hypothesis is consistent with
the alterations of the nuclear envelope in cells containing inclusion
bodies that were described in patients affected by Huntington dis-
ease and in transgenic mice expressing mutant huntingtin (Waelter
et al., 2001).
We also found that Grp78, an endoplasmic reticulum chap-
erone up-regulated during the unfolded protein response, was
strongly increased and associated to the FHL1 deposits in the
proband muscle biopsy. This finding is in agreement with pre-
vious work showing increased expression of Grp78 and unfolded
protein response in patients with RBM (Liewluck et al., 2007).
However, the association of Grp78 with aggresomes may be also
due to retrograde transport from the endoplasmic reticulum, as
hypothesized by the formation of aggresome-like inclusion bodies
induced by mutant huntingtin (Garcia-Mata et al., 2002).
The association of FHL1 with p62 we detected in the proband
muscle biopsy indicates that the mutant FHL1 protein is tar-
geted to degradative pathways. p62 is a multifunctional protein
containing a number of protein–protein interaction motifs that
are involved in protein aggregation and degradation (Moscat and
Diaz-Meco, 2009a,b). It has been hypothesized that p62 may act as
a critical ubiquitin chain-targeting factor that shuttles substrates
for proteasomal degradation (Seibenhener et al., 2004). On the
other hand, a role for p62 in aggregate formation for autophagic
degradation was also hypothesized (Komatsu et al., 2007; Kirkin
et al., 2009; Komatsu and Ichimura, 2010). The strong increase of
Beclin 1 and BNIP3 levels we detected in the patient biopsy indi-
cates that autophagy induction is taking place, likely to help the
clearance of accumulating aggregates. This is further confirmed by
the slight increase of LC3 lipidation and by the accumulation of
LC3 deposits in proximity to aggresomes in the proband muscle.
The presence of autophagic vacuoles and myelin figures further
confirms the involvement of the autophagic pathway in the patho-
physiological alterations of this patient. Interestingly, the presence
of autophagosomes and autophagic vacuoles was also reported
in muscle biopsies of RBM patients (Bertrand et al., 2014). It is
also interesting to consider that FHL1 null mice, lacking global
FHL1 expression and without aggregates accumulation, display
susceptibility to autophagy, as indicated by increased LC3 lipida-
tion in skeletal muscle (Domenighetti et al., 2014). These findings
point to a causative role of FHL1 deficiency in autophagy acti-
vation, and indicate that activation of the autophagic pathway in
FHL1-related myopathies may be a common pathophysiological
mechanism, independent from the accumulation of protein aggre-
gates. Although future studies of the autophagic flux in muscle cells
from patients and animal models for FHL1 deficiency are needed
in order to understand in detail how and to which extent deregula-
tion of autophagy contributes to the pathogenesis of FHL1-related
myopathies, our data demonstrate for the first time the coexistence
of aggresomes and autophagy in the muscle biopsy of a patient
with severe sarcopenia caused by p.C150R mutation in FHL1.
These findings add new insights in delineating the altered mecha-
nisms involved in the pathogenesis of FHL1-associated diseases.
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